The impact of COVID-19 on PRO development, collection and implementation: views of UK and Ireland professionals.
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
02
02
2023
accepted:
30
10
2023
medline:
29
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
epublish
Résumé
PROs are valuable tools in clinical care to capture patients' perspectives of their health, symptoms and quality of life. However the COVID-19 pandemic has had profound impacts on all aspects of life, in particular healthcare and research. This study explores the views of UK and Irish health professionals, third sector and pharmaceutical industry representatives and academic researchers on the impact of COVID-19 on PRO collection, use and development in clinical practice. A volunteer sample took part in a 10 question cross sectional qualitative survey, on the impact of COVID-19, administered online via Qualtrics. Demographic data was descriptively analysed, and the qualitative free text response data was subject to thematic analysis and summarised within the Strengths, Weaknesses, Opportunities and Threats (SWOT) framework. Forty nine participants took part located in a range of UK settings and professions. Participants highlighted staff strengths during the pandemic including colleagues' flexibility and ability to work collaboratively and the adoption of novel communication tools. Weaknesses were a lack of staff capacity to continue or start PRO projects and insufficient digital infrastructure to continue studies online. Opportunities included the added interest in PROs as useful outcomes, the value of electronic PROs for staff and patients particularly in relation to integration into systems and the electronic patient records. However, these opportunities came with an understanding that digital exclusion may be an issue for patient groups. Threats identified included that the majority of PRO research was stopped or delayed and funding streams were cut. Although most PRO research was on hold during the pandemic, the consensus from participants was that PROs as meaningful outcomes were valued more than ever. From the opportunities afforded by the pandemic the development of electronic PROs and their integration into electronic patient record systems and clinical practice could be a lasting legacy from the COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
PROs are valuable tools in clinical care to capture patients' perspectives of their health, symptoms and quality of life. However the COVID-19 pandemic has had profound impacts on all aspects of life, in particular healthcare and research. This study explores the views of UK and Irish health professionals, third sector and pharmaceutical industry representatives and academic researchers on the impact of COVID-19 on PRO collection, use and development in clinical practice.
METHODS
METHODS
A volunteer sample took part in a 10 question cross sectional qualitative survey, on the impact of COVID-19, administered online via Qualtrics. Demographic data was descriptively analysed, and the qualitative free text response data was subject to thematic analysis and summarised within the Strengths, Weaknesses, Opportunities and Threats (SWOT) framework.
RESULTS
RESULTS
Forty nine participants took part located in a range of UK settings and professions. Participants highlighted staff strengths during the pandemic including colleagues' flexibility and ability to work collaboratively and the adoption of novel communication tools. Weaknesses were a lack of staff capacity to continue or start PRO projects and insufficient digital infrastructure to continue studies online. Opportunities included the added interest in PROs as useful outcomes, the value of electronic PROs for staff and patients particularly in relation to integration into systems and the electronic patient records. However, these opportunities came with an understanding that digital exclusion may be an issue for patient groups. Threats identified included that the majority of PRO research was stopped or delayed and funding streams were cut.
CONCLUSIONS
CONCLUSIONS
Although most PRO research was on hold during the pandemic, the consensus from participants was that PROs as meaningful outcomes were valued more than ever. From the opportunities afforded by the pandemic the development of electronic PROs and their integration into electronic patient record systems and clinical practice could be a lasting legacy from the COVID-19 pandemic.
Identifiants
pubmed: 38010558
doi: 10.1186/s41687-023-00663-y
pii: 10.1186/s41687-023-00663-y
pmc: PMC10682296
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121Informations de copyright
© 2023. The Author(s).
Références
Qual Life Res. 2013 Nov;22(9):2265-78
pubmed: 23504544
JCO Clin Cancer Inform. 2021 May;5:615-621
pubmed: 34085537
Qual Life Res. 2012 Oct;21(8):1305-14
pubmed: 22048932
Patient. 2018 Dec;11(6):591-598
pubmed: 29968179
BMJ Open. 2021 Oct 12;11(10):e053440
pubmed: 34642200
BMJ Open. 2021 Nov 15;11(11):e051065
pubmed: 34782342
J Patient Rep Outcomes. 2018 Sep 15;2:42
pubmed: 30294712
Health Qual Life Outcomes. 2015 Oct 07;13:167
pubmed: 26446159
Qual Life Res. 2015 May;24(5):1077-85
pubmed: 25577498
J Am Med Inform Assoc. 2021 Sep 18;28(10):2265-2268
pubmed: 34244760
BMJ Open. 2021 Dec 6;11(12):e049086
pubmed: 34872995
Enferm Intensiva. 2022 Apr-Jun;33(2):77-88
pubmed: 34873389
BMJ Open. 2021 Jan 28;11(1):e042591
pubmed: 33509850
Int J Health Plann Manage. 2012 Jan-Mar;27(1):34-49
pubmed: 20603842
J Comp Eff Res. 2016 Aug;5(5):507-19
pubmed: 27427277
J Med Internet Res. 2022 Sep 19;24(9):e35828
pubmed: 36041005
J Clin Oncol. 2004 Feb 15;22(4):714-24
pubmed: 14966096
Autism Res. 2021 Jun;14(6):1078-1087
pubmed: 33759380
Psychooncology. 2022 Apr;31(4):671-675
pubmed: 35048447
J Clin Oncol. 2011 Mar 10;29(8):954-6
pubmed: 21282536
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
Psychooncology. 2020 Sep;29(9):1430-1435
pubmed: 32691451
Clin Nurse Spec. 2022 Jul-Aug 01;36(4):190-195
pubmed: 35714321
Dis Model Mech. 2020 Jun 23;13(6):
pubmed: 32764155
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 33008936
BMJ Open. 2022 Aug 3;12(8):e063279
pubmed: 35922108
Cancer Cell. 2020 Aug 10;38(2):148-149
pubmed: 32634378
Qual Life Res. 2019 Mar;28(3):621-627
pubmed: 30448911
Occup Environ Med. 2021 Nov;78(11):801-808
pubmed: 34183447
J Patient Rep Outcomes. 2020 Jan 13;4(1):4
pubmed: 31933005
J Clin Oncol. 2011 Jul 20;29(21):2910-7
pubmed: 21690465
BMJ. 2022 Jan 28;376:o257
pubmed: 35091425
Clin Infect Dis. 2022 Jan 29;74(2):278-287
pubmed: 33912905
BMJ. 2021 May 18;373:n1260
pubmed: 34006526
J Pediatr Urol. 2020 Oct;16(5):715-716
pubmed: 32713792